SCHEMBL17554391

SCHEMBL17554391

CN1CCC(Oc2ccc(OCc3ccccc3N)cc2)CC1

nearest known ligand 0.51

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 5/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
KDM1A O60341 3/20 0.48
RCOR1 Q9UKL0 3/20 0.48
MCHR1 Q99705 1/20 0.43
ALDH1A1 P00352 1/20 0.42
CARM1 Q86X55 1/20 0.42
PRMT6 Q96LA8 1/20 0.42
CDK9 P50750 1/20 0.42
EGFR P00533 1/20 0.41
ERBB2 P04626 1/20 0.41
HRH1 P35367 1/20 0.40
DRD2 P14416 3/20 0.40
DRD4 P21917 3/20 0.40
DRD3 P35462 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17554486 0.89 KDM1A (0.52) HRH3SMN1; SMN2KDM1ARCOR1MCHR1
SCHEMBL17560121 0.86 CHRM3 (0.42) HRH3SMN1; SMN2KDM1ARCOR1MCHR1
SCHEMBL17554382 0.83 SRD5A1 (0.45) KDM1ARCOR1DRD2DRD4DRD3
SCHEMBL17554458 0.80 GPR119 (0.56) KDM1A
SCHEMBL30389108 0.80 GPR119 (0.56) KDM1A
SCHEMBL17554395 0.80 HRH3 (0.55) HRH3SMN1; SMN2KDM1ARCOR1MCHR1
SCHEMBL3546661 0.78 MCHR1 (0.41) HRH3SMN1; SMN2MCHR1CARM1PRMT6
SCHEMBL17554433 0.78 MAOB (0.52) HRH3SMN1; SMN2KDM1ARCOR1MCHR1
SCHEMBL188685 0.76 HRH3 (0.65) HRH3SMN1; SMN2ALDH1A1CARM1PRMT6
SCHEMBL17554424 0.76 NPC1 (0.69) HRH3SMN1; SMN2KDM1ARCOR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3189059-B1 THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS ST EUROPEO DI ONCOLOGIA S R L (IT) 2023-02-22 EP disclosed
US-10183952-B2 Thienopyrroles as histone demethylase inhibitors ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2019-01-22 US disclosed
US-20170260197-A1 THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2017-09-14 US disclosed
EP-3189059-A2 THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS Istituto Europeo di Oncologia S.r.l. (IT) 2017-07-12 EP disclosed
WO-2016034946-A2 THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) 2016-03-10 WO disclosed
EP-2993175-A1 Thienopyrroles as histone demethylase inhibitors IEO - Istituto Europeo di Oncologia Srl (IT) 2016-03-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10183952-B2 Thienopyrroles as histone demethylase inhibitors KDM1A, KDM1B, KDM3A HRH3 354/4885SMN1; SMN2 2843/4885KDM1A 1/4885
US-20170260197-A1 THIENOPYRROLES AS HISTONE DEMETHYLASE INHIBITORS KDM1A, KDM1B, KDM3A HRH3 354/4885SMN1; SMN2 2843/4885KDM1A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.